Skip to main content
Caplight Logo









Kivu Biosciences

Kivu Biosciences

Private
San Mateo, CaliforniaHealthcare & Life Scienceshttps://kivubioscience.com/

Last Round

Series A

Oct 28, 2024

Total Funding Raised

$92M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Kivu Biosciences is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antibody-drug conjugatesADCsolid tumor oncologytargeted cancer therapybiotechclinical-stage biotechlinker-payload technologycancer drug developmentoncology therapeuticsdrug discoveryclinical trialsnext-gen oncologybiopharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kivu Biosciences Comparables

Compare Kivu Biosciences with similar companies based on industry and business-model similarity.

Kivu Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Adcentrx Therapeutics
88%
Adcendo
81%
Duality Biotherapeutics Inc
77%

Kivu Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 28, 2024

Key People

Founding team and executive leadership

Mohit Trikha

President COO

Executive Team

Kivu Biosciences Investors

Notable investors and investment history

Kivu Biosciences investors
InvestorRounds
Brabantse Ontwikkelings MaatschappijSeries A
GimvSeries A
M VenturesSeries A
HealthCapSeries A
Novo HoldingsSeries A
BioGeneration VenturesSeries A
Red Tree Venture CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 31, 2026

    Open roles increased to 6, 3x the trailing average.

  • Apr 22, 2026

    Grew 20% QoQ, from 20 to 24 employees.

Kivu Biosciences Filings

Explore SEC and related filing metadata, where available.

Kivu Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kivu Biosciences's valuation, stock price, and market status.

Is Kivu Biosciences a public or private company?

Kivu Biosciences is a private company.

What is the current stock price of Kivu Biosciences?

Kivu Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Kivu Biosciences worth (valuation)?

Valuation information for Kivu Biosciences is not publicly available.

Can I buy Kivu Biosciences stock?

Kivu Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Kivu Biosciences's last funding round?

Kivu Biosciences's most recent funding round was Series A on October 28, 2024.

Who are the main investors in Kivu Biosciences?

Key investors in Kivu Biosciences include Novo Holdings.

Will Kivu Biosciences IPO soon?

No public IPO plans have been announced for Kivu Biosciences.

How can I track Kivu Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kivu Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Mateo, California
Employee Range19
Year Founded2024
Last FundingOct 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?